Effects of inhaled dry-powder budesonide/fomoterol in moderate and severe patients with chronic obstructive pulmonary disease

To evaluate clinical efficacy of budesonide/fomoterol in single inhaler in treatment of patients with stable moderate to severe COPD).Methods 60 patients with COPD were randomly divided into theray and control groups.Baseline treatments were similar in all patients.Patients in theray group received budesonide/fomoterol inhalation twice daily via Turbuhaler for 6 months.Slow-release theophylline twice daily was additionally given to patients in control group for 6 months.Before and after the therapeutic course,tests for lung function in patients of these two groups were examined and compared with each other.Results Before the experiment,difference of FEV1/FVC and FEV1/predictive value between these two groups was not significant(P0.05).At the end of experiment,the values of FEV1/FVC and FEV1/predictive value in trial group increased in different extent than baseline values(P0.05).But the change of values of FEV1/FVC and FEV1/predictive value in control group after the experiment was not significant(P0.05).Conclusion Budesonide/fomoterol in single inhaler can improve lung function and life quality of patients with stable moderate to severe COPD,and it can also reduce the rate of hospitalization of these patients.